StockNews.com Upgrades Sanofi (NASDAQ:SNY) to Strong-Buy

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a report released on Friday.

Several other research firms have also recently commented on SNY. Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a buy rating in a research report on Friday, July 26th. Citigroup raised shares of Sanofi to a strong-buy rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.43 on Friday. The business has a fifty day moving average price of $54.34 and a 200-day moving average price of $50.52. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market capitalization of $145.45 billion, a PE ratio of 28.86, a PEG ratio of 1.62 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.95 EPS. As a group, equities analysts expect that Sanofi will post 4.25 EPS for the current fiscal year.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently modified their holdings of the company. TCTC Holdings LLC increased its stake in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC boosted its stake in Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after purchasing an additional 221 shares during the period. Wynn Capital LLC raised its position in shares of Sanofi by 4.5% during the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after buying an additional 226 shares during the last quarter. Insigneo Advisory Services LLC lifted its holdings in shares of Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after buying an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC grew its stake in Sanofi by 2.1% during the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after acquiring an additional 244 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.